Cancer News: Lung
More treatment options for non-small cell lung cancer
The drug Alectinib (Alecensa) received approval by the FDA for the treatment of patients with advanced, metastatic, ALK-positive non-small cell lung cancer.
Treatment for non-small cell lung cancer gets FDA approval
US regulators approved the monoclonal antibody necitumumab Portrazza as a first-line treatment for advanced squamous non-small cell lung cancer.
New FDA approved treatment for non-small cell lung cancer
U.S. regulators approved osimertinib for the treatment of metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
Lung cancer surgery: a beneficial option for high-risk patients
A new study revealed the effectiveness and the safety profile of surgical lung resection for high-risk patients with early stage lung cancer.
Everolimus to cover unmet health care need
The agent everolimus showed real promise in treating patients with nonfunctional neuroendocrine tumors of lung or gastrointestinal origin, a new study reveals.
Less lung toxicity in lung cancer patients with radiation therapy
Non-small cell lung cancer patients who received intensity modulated radiation therapy had lower occurrence of severe pneumonitis, a secondary analysis reported.
CT scan follow-up could prevent lung cancer's return
Patients with lung cancer patients survived longer if their management included a follow-up program based on computer tomography (CT) of the chest, a new study shows.
Nivolumab gets expanded approval to treat advanced lung cancer
U.S. regulators approved nivolumab for the treatment of patients with non-squamous non-small cell lung cancer.
Newly approved immunotherapy transforms lung cancer treatment
The breakthrough immunotherapy Keytruda got approved by the U.S. FDA to treat patients with advanced non-small cell lung cancer.
New immunotherapy shows positive results in bladder and lung cancer
Roche’s new immune-system boosting drug, atezolizumab, improved patient outcomes for lung and bladder cancer patients, according to separate phase 2 trials.
Results of cetuximab in advanced non-small cell lung cancer
A randomized trials showed that the added to chemotherapy inhibitor cetuximab failed to improve survival in patients with advanced non-small cell lung cancer.
Traditional chemotherapy with immunotherapy against lung cancer
Combining traditional chemotherapy with immunotherapy is safe for patients with advanced small cell lung cancer and non-small cell lung cancer, a new study reveals.
Combining immunotherapies for previously untreated lung cancer
Two immunotherapies, Opdivo and Yervoy can be safely and effectively combined to treat patients with previously untreated lung cancer, an early-stage study shows.
New treatment guidelines for advanced non-small cell lung cancer
The American Society of Clinical Oncology created a guideline to help doctors choose the best therapies for patients with advanced non-small cell lung cancer.
Gefitinib gets US approval for non-small cell lung cancer
Gefitinib has been approved in the US for the treatment of metastatic non-small cell lung cancer patients with specific tumor characteristics.
New lung cancer drug gets US approval as first-line treatment
AstraZeneca’s lung cancer drug, Iressa has been given the green light from US regulators, as a first-line treatment for lung cancer.
Improved outcome for lung cancer patients with combined treatments
Combining chemotherapy, radiation therapy and surgical removal of the lung may be beneficial for metastatic non-small cell lung cancer patients, a new study proposes.
Extended survival for lung cancer patients with immunotherapy drug
The immunotherapy nivolumab PD-1 found to be an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC) in a phase 3 trial.
Drug for lung cancer with genetic mutation gains EU approval
The European regulators have approved Novartis’s drug Zykadia, a treatment for lung cancer patients with a rare genetic mutation.
Gastrointestinal tumors associated with higher cancer risk
Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.
Lung cancer: lower mortality risk after statins use
Lung cancer patients who used statins in the year prior to or after a lung cancer diagnosis had lower mortality risk, researchers report.
Risk of life-threatening blood clots after surgery for lung cancer
Scientists at a large medical conference discussed the risk of pulmonary embolism and deep vein thrombosis in lung cancer patients after their surgery.
Oral contraceptives: not associated with lung cancer risk
A large prospective study of lung cancer found that oral contraceptives and hormone therapy use are not associated with risk of lung cancer.
Immunotherapy drug holds promise for lung cancer patients
A new study of the immunotherapy drug, pembrolizumab, showed safe and favorable durable outcomes to patients with advanced, non-small cell lung cancer.
New drug gives hope to non-small cell lung cancer patients
The drug AZD9291 showed significant antitumor efficacy as it delayed the progression of the disease in non-small cell lung cancer patients.
Physical activity reduces risk of development in lung cancer patients
Lung cancer patients reduced symptoms, increased exercise tolerance and improved quality of life through physical activity.
New immunotherapy drug for lung cancer gets early FDA approval
The FDA approved the drug Opdivo for the treatment of patients with advanced non-small cell lung cancer with progression on/after platinum-based chemotherapy.
New lung cancer drug gets EU recommendation
Novartis’ treatment for lung cancer, Zykadia, got recommendation for approval from European health regulators.
Follow-up scans proved beneficial for lung cancer patients
New research illustrates the high value of PET/CT scans for lung cancer patients, based on how much they can help clinical assessment and management of patients.
Could a gene link lung cancer with Parkinson's disease?
A gene mutation, previously related with early-onset Parkinson's disease, was found to be associated with lung cancer.